2023 Inhalers Pipeline Research Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

DUBLIN, Jan. 17, 2024 /PRNewswire/ -- The "Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to  ResearchAndMarkets.com's offering.

Inhalers Pipeline Report provides comprehensive information about the Inhalers pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Inhaler devices deliver medication to the lungs.

The comprehensive report provides in-depth coverage of the rapidly evolving field of Inhalers, offering a thorough analysis of various aspects. It meticulously reviews the intricate details of major pipeline products, including comprehensive product descriptions, licensing agreements, collaborative efforts, and other pivotal developmental activities shaping the landscape of inhalers.

Furthermore, the report conducts a comprehensive examination of the major players actively driving innovation in Inhalers, presenting an extensive catalog of their ongoing pipeline projects. This coverage spans the entire spectrum of development stages, ranging from early conceptualization to products in the approved and issued stages, providing a holistic view of the dynamic field of inhaler development.

Additionally, the report offers essential clinical trial data related to ongoing trials associated with these pipeline products, ensuring stakeholders are well-informed about the latest advancements in this crucial healthcare sector. It also keeps a keen eye on recent developments within the inhalers segment and the broader industry, ensuring that stakeholders stay up-to-date with the latest trends and breakthroughs in inhaler technology and healthcare delivery.

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Inhalers under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Inhalers Overview

3 Products under Development
3.1 Inhalers - Pipeline Products by Stage of Development
3.2 Inhalers - Pipeline Products by Segment
3.3 Inhalers - Pipeline Products by Territory
3.4 Inhalers - Pipeline Products by Regulatory Path
3.5 Inhalers - Pipeline Products by Estimated Approval Date
3.6 Inhalers - Ongoing Clinical Trials

4 Inhalers - Pipeline Products under Development by Companies
4.1 Inhalers Companies - Pipeline Products by Stage of Development
4.2 Inhalers - Pipeline Products by Stage of Development

5 Inhalers Companies and Product Overview

6 Inhalers- Recent Developments

7 Appendix

A selection of companies mentioned in this report includes

• 1nhaler Ltd
• Acorda Therapeutics Inc
• Advent Pharmaceuticals Pty Ltd
• Aerami Therapeutics Inc
• Aespira Ltd.
• AKELA Pharma Inc. (Inactive)
• AsMedic Ltd.
• Bayer AG
• Bellerophon Therapeutics Inc
• Cambridge Healthcare Innovations Ltd
• Cipla Ltd
• Covinhaler LLP
• Creare LLC
• De Motu Cordis Pty Ltd
• DMK Pharmaceuticals Corp
• Drexel University
• Eli Lilly and Co
• Engage Therapeutics Inc
• Findair Sp zoo
• FocusStart LLC
• Glenmark Pharmaceuticals Ltd
• GSK plc
• Hovione Technology Ltd
• Iconovo AB
• Lupin Pharmaceuticals Inc
• MannKind Corp
• Medihale Ltd (Inactive)
• Monash University
• Nektar Therapeutics
• North Carolina State University
• Novartis AG
• Ology Bioservices Inc
• OPKO Health Inc
• OtiTopic Inc
• Pai Life Sciences Inc
• Phargentis SA
• Pharmaxis Ltd
• Pneuma Respiratory Inc
• Pure Scientific Technologies Inc
• PureIMS BV
• Quench Medical Inc
• Resolve Digital Health Inc
• Respira Therapeutics Inc
• Respirent Pharmaceuticals Co Ltd
• Rhinomed Ltd
• Sandoz International GmbH
• Seng Vital International GmbH
• Sheffield Hallam University
• Shin Nippon Biomedical Laboratories Ltd
• Sinsin Pharmaceutical Co Ltd
• Softhale NV
• Spyryx Biosciences Inc (Inactive)
• Teva Pharmaceutical Industries Ltd
• Transpire Bio Inc
• University of Kansas
• University of Sydney
• University of Texas Medical Branch at Galveston
• Uscom Ltd
• Vectura Group Plc
• Veoli Ltd
• Verona Pharma Plc
• Virginia Commonwealth University

For more information about this report visit https://www.researchandmarkets.com/r/3awdnp

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected] 
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets